{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:18Z","timestamp":1791476058405,"version":"4.3.4"},"reference-count":96,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Within the past few years, many new therapies have emerged for psoriasis and psoriatic arthritis (PsA). Current topical therapies\u2014including corticosteroids, vitamin D analogs, tapinarof, and roflumilast\u2014remain the mainstay for mild disease, while oral systemic and biologic options are for moderate to severe cases. Biologics\u2014such as Tumor necrosis factor-alpha (TNF-alpha), Interleukin 12\/23 (IL-12\/23), Interleukin-17 (IL-17), and Interleukin-23 (IL-23)\u2014have revolutionized care by providing highly effective and safer alternatives. Oral small molecules, including Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitors, further expand the therapeutic options. Objectives: The goal for this review article was to examine current and latest treatments for psoriasis and PsA and discuss whether these emerging therapeutic options address the unmet needs of current treatments. Methods: The search for this review article included PubMed, Google Scholar, and ClinicalTrials.gov for relevant articles and current clinical trials using keywords. Results: A wide range of novel psoriatic and PsA therapies are currently undergoing clinical trials. These include selective JAK inhibitors, TYK2 inhibitors, retinoic acid-related orphan receptor (ROR\u03b3T) inhibitors, oral IL-23 receptor inhibitors, oral IL-17A inhibitors, nanobody products, sphingosine-1-phosphate (S1P1R) antagonists, A3 adenosine receptor (A3AR) agonists, heat shock protein (HSP) 90 inhibitors, and rho-associated protein kinases (ROCK-2) inhibitors. Conclusions: These different mechanisms of action not only expand treatment options but may offer potential solutions for patients who do not achieve adequate response with existing therapies. However, the safety and contraindications of these newer agents remain an important consideration to ensure appropriate patient selection and minimize potential risks. Certain mechanisms may pose increased risks for infection, cardiovascular manifestations, malignancy, or other immune-related adverse events, necessitating careful monitoring and individualized treatment decisions. Ongoing clinical research aims to address unmet needs for patients who do not respond to previous agents to achieve sustained remission, monitor long-term safety outcomes, and assess patient preferences for delivery, including a preference for oral delivery. Oral IL-23 inhibitors hold potential due to their robust safety profiles. In contrast, oral IL-17 inhibitors and TYK-2 inhibitors are effective but may present side effects that could impact their acceptability. It is essential to balance efficacy, safety, and patient preferences to guide the selection of appropriate therapies.<\/jats:p>","DOI":"10.3390\/jcm14041312","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T03:41:47Z","timestamp":1739763707000},"page":"1312","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Therapeutic Advancements in Psoriasis and Psoriatic Arthritis"],"prefix":"10.3390","volume":"14","author":[{"given":"Robin C.","family":"Yi","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7035-2217","authenticated-orcid":false,"given":"Maya","family":"Akbik","sequence":"additional","affiliation":[{"name":"Medical College of Georgia at Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-9424","authenticated-orcid":false,"given":"Logan R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Klionsky","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"},{"name":"Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"},{"name":"Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1759720X21998279","DOI":"10.1177\/1759720X21998279","article-title":"Psoriatic arthritis and the association with cardiometabolic disease: A narrative review","volume":"13","author":"Karmacharya","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_2","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can. Fam. Physician"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Deng, Z., Wang, S., Wu, C., and Wang, C. (2023). IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1124628"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tsiogka, A., Gregoriou, S., Stratigos, A., Soulaidopoulos, S., Rompoti, N., Panagakis, P., Papoutsaki, M., Kostakis, P., Kontochristopoulos, G., and Tsioufis, K. (2023). The Impact of Treatment with IL-17\/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and\/or Psoriatic Arthritis: A Systematic Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020318"},{"key":"ref_5","first-page":"37","article-title":"Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas","volume":"3","author":"Zeichner","year":"2010","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ibbotson, S.H. (2018). A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00184"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.sder.2010.03.006","article-title":"Phototherapy in pediatric patients: Choosing the appropriate treatment option","volume":"29","author":"Pugashetti","year":"2010","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijd.IJD_169_17","article-title":"Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach","volume":"62","author":"Das","year":"2017","journal-title":"Indian. J. Dermatol."},{"key":"ref_9","first-page":"46","article-title":"The rationale behind topical vitamin d analogs in the treatment of psoriasis: Where does topical calcitriol fit in?","volume":"3","author":"Kim","year":"2010","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_10","first-page":"S3","article-title":"Topical Management of Plaque Psoriasis\u2014A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation","volume":"16","author":"Bruno","year":"2023","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"212521","DOI":"10.7573\/dic.212521","article-title":"Atopic dermatitis: A review of topical nonsteroid therapy","volume":"7","author":"Papier","year":"2018","journal-title":"Drugs Context"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaad.2004.07.011","article-title":"Tacrolimus ointment is effective for facial and intertriginous psoriasis","volume":"51","author":"Lebwohl","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/87551225231193057","article-title":"Noncorticosteroid Topical Therapies for the Treatment of Plaque Psoriasis: A Narrative Review","volume":"39","author":"Chandy","year":"2023","journal-title":"J. Pharm. Technol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70041","DOI":"10.1111\/srt.70041","article-title":"A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis","volume":"30","author":"Ghani","year":"2024","journal-title":"Skin. Res. Technol."},{"key":"ref_16","first-page":"392","article-title":"The possibilities and principles of methotrexate treatment of psoriasis\u2014The updated knowledge","volume":"31","year":"2014","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bedoui, Y., Guillot, X., Selambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M.C., Ralandison, S., and Gasque, P. (2019). Methotrexate an Old Drug with New Tricks. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205023"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000366501","article-title":"Acute severe methotrexate toxicity in patients with psoriasis: A case series and discussion","volume":"229","author":"Yelamos","year":"2014","journal-title":"Dermatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13934","DOI":"10.1111\/dth.13934","article-title":"Cyclosporin in dermatology: A practical compendium","volume":"33","author":"Amber","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Li, H.J., Lin, S.H., Wang, Y.Q., Chen, L., Zheng, X.X., and Wei, L.X. (2024). Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: A retrospective cohort study. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.01276-24"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dth.12086","article-title":"Acitretin","volume":"26","author":"Ortiz","year":"2013","journal-title":"Dermatol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0190-9622(99)70359-2","article-title":"Acitretin in psoriasis: An overview of adverse effects","volume":"41","author":"Katz","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","article-title":"A novel treatment for psoriatic arthritis: Janus kinase inhibitors","volume":"133","author":"Chen","year":"2020","journal-title":"Chin. Med. J. Engl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis","volume":"58","author":"Truong","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the Treatment of Psoriatic Disease","volume":"23","author":"Le","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2023-2-7","article-title":"Deucravacitinib for the treatment of psoriatic arthritis: The evidence so far","volume":"12","author":"Martins","year":"2023","journal-title":"Drugs Context"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jmv.25304","article-title":"Acute pain and postherpetic neuralgia related to Varicella zoster virus reactivation: Comparison between typical herpes zoster and zoster sine herpete","volume":"91","author":"Drago","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s13555-024-01166-4","article-title":"Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review","volume":"14","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study","volume":"43","author":"Coates","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25","author":"Maza","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/ard.62.4.291","article-title":"Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: A double blind randomised placebo controlled trial","volume":"62","author":"Gerards","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2183729","DOI":"10.1080\/09546634.2023.2183729","article-title":"Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: A case series","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","article-title":"TNFalpha blockade in human diseases: An overview of efficacy and safety","volume":"126","author":"Lin","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_42","first-page":"169","article-title":"Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis","volume":"8","author":"Kivelevitch","year":"2014","journal-title":"Biologics"},{"key":"ref_43","first-page":"115","article-title":"Infliximab for the treatment of plaque psoriasis","volume":"2","author":"Gall","year":"2008","journal-title":"Biologics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/1744666X.2014.878649","article-title":"Ustekinumab for the treatment of psoriatic arthritis","volume":"10","author":"Wofford","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_46","first-page":"463","article-title":"Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population","volume":"15","author":"Berman","year":"2021","journal-title":"Biologics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2017.53.5.2613690","article-title":"Brodalumab: The first anti-IL-17 receptor agent for psoriasis","volume":"53","author":"Puig","year":"2017","journal-title":"Drugs Today"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Argenziano, G., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., and Damiani, G. (2023). Brodalumab for the treatment of plaque psoriasis in a real-life setting: A 3\u2009years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front. Med., 10.","DOI":"10.3389\/fmed.2023.1196966"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/1744666X.2021.1967748","article-title":"Bimekizumab: A dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis","volume":"17","author":"Ali","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41584-022-00823-2","article-title":"Bimekizumab safe and effective for AS and PsA in long-term trials","volume":"18","author":"Phillips","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2133531","DOI":"10.1080\/09546634.2022.2133531","article-title":"Guselkumab, tildrakizumab, and risankizumab in a real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Elgaard","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1080\/14656566.2024.2419563","article-title":"Pharmacotherapeutic management of psoriatic disease: Addressing psoriatic arthritis and cutaneous manifestations","volume":"25","author":"Yi","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.19393","article-title":"Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)","volume":"184","author":"Gordon","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/tcrm.2006.2.4.389","article-title":"Infliximab (Remicade) in the treatment of psoriatic arthritis","volume":"2","author":"Mease","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and Efficacy of Intravenous Golimumab in Patients with Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","article-title":"Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis","volume":"2","author":"Savage","year":"2015","journal-title":"Rheumatol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","article-title":"Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13555-017-0187-0","article-title":"Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials","volume":"7","author":"Nakamura","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1111\/jdv.17124","article-title":"Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1","volume":"35","author":"Cantrell","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","first-page":"e15378","article-title":"Risankizumab shows high efficacy and maintenance in improvement of response until week 52","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial","volume":"11","author":"Kristensen","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrd3974","article-title":"Challenges and approaches for the development of safer immunomodulatory biologics","volume":"12","author":"Sathish","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the Patient with Psoriasis and Metabolic Comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051001"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Carmona-Rocha, E., Rusinol, L., and Puig, L. (2024). New and Emerging Oral\/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics, 16.","DOI":"10.20944\/preprints202401.0800.v1"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Caiazzo, G., Caiazzo, A., Napolitano, M., Megna, M., Potestio, L., Fornaro, L., Parisi, M., Luciano, M.A., Ruggiero, A., and Testa, A. (2023). The Use of JAK\/STAT Inhibitors in Chronic Inflammatory Disorders. J. Clin. Med., 12.","DOI":"10.3390\/jcm12082865"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40744-019-00167-6","article-title":"Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study","volume":"6","author":"Genovese","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Dragotto, M., D\u2019Onghia, M., Trovato, E., Tognetti, L., Rubegni, P., and Calabrese, L. (2024). Therapeutic Potential of Targeting the JAK\/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition. J. Clin. Med., 13.","DOI":"10.3390\/jcm13113091"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/24755303231201336","article-title":"Deucravacitinib: A novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis","volume":"8","author":"Kingston","year":"2023","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: A multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine Kinase 2 Inhibition with Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Tang, L., Yang, X., Liang, Y., Xie, H., Dai, Z., and Zheng, G. (2018). Transcription Factor Retinoid-Related Orphan Receptor gammat: A Promising Target for the Treatment of Psoriasis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01210"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jpha.2023.05.009","article-title":"Small molecule inhibitors of RORgammat for Th17 regulation in inflammatory and autoimmune diseases","volume":"13","author":"Zeng","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Bassolas-Molina, H., Raymond, E., Labadia, M., Wahle, J., Ferrer-Pic\u00f3n, E., Panzenbeck, M., Zheng, J., Harcken, C., Hughes, R., and Turner, M. (2018). An ROR\u03b3t Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn\u2019s Disease Patients. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02307"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Drakos, A., Torres, T., and Vender, R. (2024). Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010111"},{"key":"ref_93","unstructured":"Kaufman, M.B. (2025, February 08). Sonelokimab Promising for Patients with PsA\u2014The Rheumatologist. Available online: www.the-rheumatologist.org\/article\/sonelokimab-promising-for-patients-with-psa."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"ftw063","DOI":"10.1093\/femspd\/ftw063","article-title":"Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection","volume":"74","author":"Tiper","year":"2016","journal-title":"Pathog. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"17562864221133163","DOI":"10.1177\/17562864221133163","article-title":"S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: A narrative review","volume":"15","author":"Constantinescu","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A(3) Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:35:32Z","timestamp":1760027732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":96,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041312"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041312","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,16]]}}}